Keros Therapeutics (NASDAQ:KROS) Research Coverage Started at Wells Fargo & Company

Wells Fargo & Company started coverage on shares of Keros Therapeutics (NASDAQ:KROS) in a report published on Monday, MarketBeat Ratings reports. The firm issued an overweight rating and a $26.00 price target on the stock.

Several other equities analysts have also weighed in on KROS. HC Wainwright reduced their target price on shares of Keros Therapeutics from $25.00 to $20.00 and set a “buy” rating on the stock in a report on Friday, August 8th. Weiss Ratings restated a “sell (d)” rating on shares of Keros Therapeutics in a report on Wednesday, October 8th. Seven analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Keros Therapeutics currently has an average rating of “Hold” and an average target price of $30.00.

Keros Therapeutics Stock Up 1.0%

Shares of KROS opened at $15.56 on Monday. The firm has a market cap of $474.11 million, a PE ratio of 50.20, a price-to-earnings-growth ratio of 1.99 and a beta of 0.97. The company’s fifty day moving average is $15.38 and its two-hundred day moving average is $14.33. Keros Therapeutics has a fifty-two week low of $9.12 and a fifty-two week high of $72.37.

Keros Therapeutics (NASDAQ:KROS) last announced its quarterly earnings results on Wednesday, August 6th. The company reported ($0.76) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.14) by $0.38. The company had revenue of $0.02 million for the quarter, compared to analyst estimates of $3.83 million. Keros Therapeutics had a net margin of 8.06% and a return on equity of 2.96%. Keros Therapeutics’s revenue for the quarter was up 49002.7% on a year-over-year basis. During the same quarter last year, the business earned ($1.25) EPS. As a group, equities research analysts anticipate that Keros Therapeutics will post -4.74 earnings per share for the current year.

Insider Buying and Selling at Keros Therapeutics

In related news, major shareholder Pontifax Management 4 G.P. (20 sold 4,787,331 shares of Keros Therapeutics stock in a transaction on Wednesday, October 15th. The shares were sold at an average price of $17.75, for a total transaction of $84,975,125.25. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, major shareholder Adar1 Capital Management, Llc sold 5,389,264 shares of Keros Therapeutics stock in a transaction on Wednesday, October 15th. The stock was sold at an average price of $17.75, for a total transaction of $95,659,436.00. The disclosure for this sale can be found here. Insiders own 20.60% of the company’s stock.

Institutional Investors Weigh In On Keros Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. CWM LLC increased its stake in Keros Therapeutics by 10,157.7% during the 1st quarter. CWM LLC now owns 2,667 shares of the company’s stock worth $27,000 after buying an additional 2,641 shares during the period. Farther Finance Advisors LLC bought a new stake in shares of Keros Therapeutics in the 3rd quarter worth about $47,000. Tower Research Capital LLC TRC increased its position in shares of Keros Therapeutics by 149.2% in the 2nd quarter. Tower Research Capital LLC TRC now owns 3,153 shares of the company’s stock worth $42,000 after purchasing an additional 1,888 shares during the last quarter. Police & Firemen s Retirement System of New Jersey increased its position in shares of Keros Therapeutics by 29.7% in the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 8,257 shares of the company’s stock worth $110,000 after purchasing an additional 1,892 shares during the last quarter. Finally, New York State Common Retirement Fund increased its position in shares of Keros Therapeutics by 264.1% in the 2nd quarter. New York State Common Retirement Fund now owns 10,616 shares of the company’s stock worth $142,000 after purchasing an additional 7,700 shares during the last quarter. Hedge funds and other institutional investors own 71.56% of the company’s stock.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.